• Antibe Therapeutics (TSXV:ATE) anti-inflammatory drug ATB-352 has demonstrated encouraging results in a research publication.
  • The research article was published in the peer-reviewed biomedical journal, “Antioxidant and Redox Signaling”.
  • In the study, ATB-352 provided greater pain relief than other similar drugs, and was gentler on the gastrointestinal tract.
  • Antibe’s share price is down 4.84 per cent, with shares currently trading at $0.59 apiece.

Pharmaceutical company Antibe Therapeutics (ATE) has welcomed the publication of a research article, which shows the positive results of their anti-inflammatory drug. 

The multi-national study was named “Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids”. The article was published in the leading international peer-reviewed biomedical journal, “Antioxidant and Redox Signaling”.

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ketoprofen are a common treatment for severe pain. However, ketoprofen, one of the more potent NSAIDs, can cause serious damage to the gastrointestinal tract (GI tract).

Antibe has developed ATB-352 as a GI-friendly, non-addictive alternative for treating post-surgical pain.

The research paper described a series of studies in which ATB-352 demonstrated superior results to other similar drugs. 

In particular, ATB-352 provided much greater pain relief than ketoprofen did. According to the study, the drug was over three times more potent in relieving pain than its rival.

ATB-352 also caused no damage to the GI tract, even in very high doses. Ketoprofen, in comparison, caused an increase in the severity of bleeding ulcers in the stomach and intestines.

The international study was led by Antibe’s Chief Scientific Officer, Dr John Wallace. It also included researchers from the University of Calgary in Canada, the University of Sao Paulo in Brazil, the University of Campinas in Brazil, and Umea University in Sweden.

Antibe’s share price is down 4.84 per cent, with shares currently trading at $0.59 apiece at 11:40am EST.

More From The Market Online

Voyageur Pharmaceuticals signs $2.6M contract in Latin America

Voyageur Pharmaceuticals (TSXV:VM) announces its first international distribution agreement with a C$2.6 million commitment.
BriaCell Therapeutics Corp

BriaCell to report positive cancer research at medical convention

BriaCell Therapeutics (TSX:BCT) will present positive clinical data of Bria-IMT at the 2024 American Society of Clinical Oncology in Chicago.

Cloud DX among leading remote patient monitoring suppliers in Canada

Cloud DX (TSXV:CDX) gives an update on its remote patient monitoring deal with the British Columbia Provincial Health Services Authority.